Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VX-745. Vertex Pharmaceuticals.

J J Haddad1

  • 1Tayside Institute of Child Health, Faculty of Medicine, Dentistry & Nursing, Ninewells Hospital and Medical School, University of Dundee, Scotland, UK. j.j.haddad@dundee.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endotoxin-mediated regulation of nuclear factor-kappaB nuclear translocation and activation in the hippocampus of the central nervous system: modulation by intracerebroventricular treatment with thymulin and the immunomodulatory role of the IkappaB-alpha/pIkappaB-alpha pathway.

Neuroscience·2009
Same author

Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology.

Cytokines, cellular & molecular therapy·2002
Same author

The role of the sympathetic efferents in endotoxin-induced localized inflammatory hyperalgesia and cytokine upregulation.

Neuropharmacology·2002
Same author

Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-alpha biosynthesis.

British journal of pharmacology·2002
Same author

L-Buthionine-(S,R)-sulfoximine, an irreversible inhibitor of gamma-glutamylcysteine synthetase, augments LPS-mediated pro-inflammatory cytokine biosynthesis: evidence for the implication of an IkappaB-alpha/NF-kappaB insensitive pathway.

European cytokine network·2002
Same author

Glutathione depletion is associated with augmenting a proinflammatory signal: evidence for an antioxidant/pro-oxidant mechanism regulating cytokines in the alveolar epithelium.

Cytokines, cellular & molecular therapy·2001
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

VX-745, an inhibitor of mitogen-activated protein kinase (MAPK), is being developed for rheumatoid arthritis (RA). It targets p38 MAPK, suppressing inflammatory mediators like interleukin-1beta and tumor necrosis factor-alpha.

Area of Science:

  • Pharmacology
  • Immunology
  • Drug Development

Background:

  • Rheumatoid arthritis (RA) is a chronic inflammatory disease.
  • Mitogen-activated protein kinase (MAPK) signaling pathways play a role in RA pathogenesis.
  • Interleukin (IL)-1beta and tumor necrosis factor (TNF)alpha are key inflammatory mediators in RA.

Purpose of the Study:

  • To evaluate VX-745, a small-molecule inhibitor of MAPK, as a potential treatment for rheumatoid arthritis.
  • To assess the clinical efficacy and pharmacodynamic effects of VX-745 in adult RA patients.

Main Methods:

  • Phase II clinical trials, including randomized, double-blind, placebo-controlled studies.
  • Evaluation of clinical response rates, patient-reported outcomes, and pharmacodynamic markers.

Related Experiment Videos

  • In vitro studies demonstrating activity against p38 MAPK isotypes (p38alpha, p38beta, p38gamma).

    • Main Results:

    • VX-745 demonstrated activity against multiple p38 MAPK isotypes.
    • Targeting p38 MAPK with VX-745 suppressed the release of inflammatory mediators (IL-1beta, TNFalpha).
    • Ongoing phase II trials investigated clinical response and pharmacodynamic markers in RA patients.

    Conclusions:

    • VX-745 shows potential as an anti-inflammatory agent for rheumatoid arthritis by inhibiting p38 MAPK.
    • Suppression of key inflammatory mediators suggests a therapeutic mechanism for RA.
    • Further clinical evaluation is warranted to confirm the efficacy and safety of VX-745 for RA treatment.